Clinical trials: Streptococcus Pneumoniae
Streptococcus Pneumoniae Carriage, Pneumococcal Colonization
Whole Genome-Based Surveillance of Nasopharyngeal Pneumococcal Carriage in Vietnamese Children
This hospital-based cross-sectional study aims to determine the prevalence and serotype distribution of nasopharyngeal Streptococcus pneumoniae carriage among children aged 2-59 months hospitalized with acute respiratory symptoms…
- Conditions
- Streptococcus Pneumoniae Carriage, Pneumococcal Colonization, Acute Respiratory Symptoms
- Trial name
- NCT07562529
- Where
- Vietnam
- Volunteers
- 530 people
- Sponsor
- Phuc Huu Phan
Healthy, Immunisation Against Streptococcus Pneumoniae
Phase I Study With V-212 Vaccinations in Healthy Adult Volunteers
Virometix AG, is conducting research into a vaccine (V-212) to prevent pneumococcal disease, which is any type of illness caused by infection with a bacterium called Streptococcus pneumoniae (S. pneumoniae).
- Trial name
- NCT06975319
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Virometix
Streptococcus Pneumoniae Infection
Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
This clinical trial consists of Phase I and Phase II. The objective is to evaluate the safety and immunogenicity of the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) in individuals aged 2 months…
- Trial name
- NCT07600983
- Testing
- 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M), PCV24 vaccine (dose H), PCV24 vaccine (dose M)
- Where
- 2 sites in China
- Volunteers
- 854 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Streptococcus Pneumoniae
A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
The purpose of this study is to learn about the safety and tolerability of a pneumococcal vaccine in adults. Participants will receive either: an experimental PG4 vaccine a PG4 vaccine comparator a standard 20vPnC vaccine…
- Trial name
- NCT07086677
- Testing
- PG4 vaccine in Buffer 1 with low dose PA-001, PG4 in Buffer 1 with low dose PA-002, PG4 in Buffer 1 with high dose PA-001
- Where
- 20 sites in United States
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Pfizer
Nasopharyngeal Carriage of Streptococcus Pneumoniae
Pneumococcal Carriage, Serotypes, and Antibiotic Resistance in Malaysian Children: A Multi-Centre Study
The goal of this observational study is to determine the prevalence, serotype distribution, and antimicrobial resistance patterns of nasopharyngeal carriage of Streptococcus pneumoniae in Malaysian children aged ≤5 years…
- Trial name
- MY-PNEUMO2 (NCT07545876)
- Where
- 4 sites in Malaysia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- IMU University, Malaysia
Vaccine, Streptococcus Pneumoniae
Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma
The French Public Health Council recommended pneumococcal vaccination combined strategy for all immunocompromised patients in 2012.
- Conditions
- Vaccine, Streptococcus Pneumoniae, Lymphoma, Non-Hodgkin
- Trial name
- HEMATOVAC (NCT04460235)
- Testing
- Prevenar 13 + Pneumovax 23, PREVENAR20
- Where
- 7 sites in France
- Volunteers
- 160 people
- Sponsor
- Poitiers University Hospital
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Streptococcus Pneumoniae Infection
Prevention of Pneumococcal Infections: Impact Collaborative Medico-pharmaceutical Care Structured to Improve Vaccination Coverage of Patients at Risk.
In France, Streptococcus pneumoniae is the leading agent bacterial involved in community lung disease and meningitis. The frequency of these infections and their mortality increase significantly in those at risk such as patients…
- Trial name
- OPTIVACC (NCT05060146)
- Testing
- Structured medico-pharmaceutical collaboration
- Where
- 9 sites in France
- Volunteers
- 646 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
13-valent Pneumococcal Vaccine, Streptococcus Pneumoniae
An Evaluation of PCV13 Vaccine Schedules, Comparing Impact of 2+1 vs 3+0 on Pneumococcal Carriage in Blantyre, Malawi
Pneumococcal conjugate vaccines (PCV) have been shown to be effective against invasive pneumococcal disease (IPD; including pneumococcal meningitis and sepsis) and all-cause mortality among young children when introduced into…
- Trial name
- PAVE (NCT04078997)
- Testing
- nasopharyngeal swab
- Where
- Malawi
- Volunteers
- 3,507 people, healthy volunteers welcome
- Sponsor
- University of Liverpool
Streptococcus Pneumoniae
Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections
Streptococcus pneumoniae is a gram-positive (GP) bacteria responsible for common infections such as community-acquired pneumonia (CAP), as well as complicated infections such as bacteremia, infective endocarditis and meningitis.
- Trial name
- NCT06096025
- Testing
- pneumoniae bacteremia therapy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Methodist Health System
Streptococcus Pneumoniae Pneumonia
Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
In the treatment of pneumococcal diseases, the common use of penicillin-based antimicrobial agents has led to drug resistance, which has become a global challenge. Therefore, disease prevention through vaccination is essential.
- Trial name
- NCT07035054
- Testing
- low dose-1, low dose-2, high dose
- Where
- China
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Streptococcus Pneumoniae Pneumonia
PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
In the treatment of pneumococcal diseases, the common use of penicillin-based antimicrobial agents has led to drug resistance, which has become a global challenge. Therefore, disease prevention through vaccination is essential.
- Trial name
- NCT07025876
- Testing
- low dose PCV24, high dose PCV24, PPV23
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
HIV Infections, Streptococcus Pneumoniae
Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting
Purpose: To study the immune response of the newly licensed pneumococcal conjugate vaccine (PCV) in comparison to the pneumococcal polysaccharide vaccine (PPV) to determine if a significantly better immunologic response to…
- Trial name
- NCT00622843
- Testing
- pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine
- Where
- 6 sites in United States
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Streptococcus Pneumoniae Infections
Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine
This clinical study aims to evaluate the mutual influence of combined administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine in the target population
- Trial name
- NCT06817187
- Testing
- 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed), Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)
- Where
- China
- Volunteers
- 1,110 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Streptococcus Pneumoniae Infection, Legionella Pneumophila Serogroup 1 Infection
Curian S. Pneumo/Legionella Assay Beta Clinical Trial Protocol
Beta trial to evaluate the preliminary clinical performance of the Curian S. pneumo/Legionella assay for its use in the qualitative detection of Streptococcus pneumoniae and/or Legionella pneumophila serogroup 1 antigens in human…
- Trial name
- NCT05681156
- Testing
- N/A- There is no intervention.
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Meridian Bioscience, Inc.
Pneumococcal Infection, Streptococcus Pneumoniae Infection
The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants
Before the introduction of pneumonia vaccines in 2000, between 700,000 - 1 million children died each year as a result of infection with the bacteria Streptococcus pneumoniae and the resulting diseases, namely, meningitis, sepsis…
- Conditions
- Pneumococcal Infection, Streptococcus Pneumoniae Infection, Invasive Pneumococcal Disease, Protection Against
- Trial name
- FPCV (NCT03489018)
- Testing
- PCV10, PCV13
- Where
- Kenya
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Streptococcus Pneumoniae Infection
Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants
This study is a phase III clinical trial to evaluate the immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine (multivalent conjugate) in infants aged 2 months (at least 6 weeks) and 3 months.
- Trial name
- NCT05759520
- Testing
- 13-valent pneumococcal conjugate vaccine (multivalent conjugate), Prevenar 13
- Where
- 5 sites in China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Fosun Adgenvax Biopharmaceutical Co.,Ltd.
Invasive Pneumococcal Disease, Protection Against, Streptococcus Pneumoniae Infection
CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study
This study is assessing if a reduced dosing schedule (1+1) of the 13-valent pneumococcal conjugate vaccine (PCV13) is non-inferior to the currently used schedule used in most of Canada.The vaccine is currently usually given as 3…
- Trial name
- NCT03384589
- Testing
- PCV13
- Where
- Canada
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Streptococcus Pneumoniae Infection
A Controlled Human Pneumococcal Infection Model (PIM) Study
Infection with Streptococcus pneumoniae (the pneumococcus) is the leading cause of pneumonia, bacterial meningitis and bacteraemia worldwide in the very young and the elderly.
- Trial name
- PIM (NCT05361499)
- Testing
- Sp_6B, Amoxicillin 500 mg
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Community-acquired Pneumonia, Streptococcus Pneumoniae Infection
Determination of the Utility of Pfizer's Pneumococcal Urine Antigen Test in Children 5 Years of Age or Younger With Community Acquired Pneumonia in Guatemala
This prospective case-control study aims to evaluate the utility and establish laboratory thresholds for a multi-serotype urine antigen test for the diagnosis of pneumococcal community acquired pneumonia in children 5 years of…
- Trial name
- NCT03696303
- Testing
- Urinary antigen detection assay
- Where
- 3 sites in Guatemala
- Volunteers
- 959 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver